Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Kevin McCarthy ousted as House Speaker by Republican rebels
    • ‘Now what?’: Kevin McCarthy’s historic downfall stuns Washington
    • India tells Canada to withdraw dozens of diplomatic staff
    • EU estimates Ukraine entitled to €186bn after accession
    • Germany becomes scapegoat in Poland’s bitter election campaign
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Revolut strikes share deal with SoftBank to remove barrier to UK licence
      • Blackstone funds legal action over soured Bain Capital deal
      • News updates from October 3: McCarthy ousted as House speaker, Japanese yen falls through 150 level
      • Hedge funds Millennium and Schonfeld in advanced partnership talks
      • The London office market is becoming harder work
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Bond sell-off intensifies as long-term US yields hit 16-year high
      • Revolut strikes share deal with SoftBank to remove barrier to UK licence
      • Live news: US Democrats express concerns over potential Saudi Arabia- Israel deal
      • News updates from October 3: McCarthy ousted as House speaker, Japanese yen falls through 150 level
      • Hedge funds Millennium and Schonfeld in advanced partnership talks
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Italians have embraced ‘fake English’
      • Britain is Europe’s haven from the hard right
      • Can China overcome its demographic deficit?
      • The return of American isolationism
      • Chief executives really need to lengthen their attention spans
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Why personal conduct is a growing risk for business
      • The ghastly modern office needs a reboot
      • ‘Talk to everyone you can’: Plaid’s Zach Perret on navigating a failed sale and Covid upheaval
      • Labour conference will be so full of execs it will look like Davos, only in Liverpool
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • How to look rich
      • David Bowie — six songs that shook the world of music
      • Climate change leads homebuyers to seek a place not in the sun
      • At home with Frankel, the racehorse turned super-stud
      • Partygate, Channel 4 review — Covid-era docudrama pulls no punches
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Biogen Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Thursday, 6 July, 2023
      Dementia
      US regulators approve first drug to slow progression of Alzheimer’s

      Move by Food and Drug Administration paves way for millions of Americans to access medicine

      Vials and packaging for the medication Leqembi
    • Monday, 8 May, 2023
      Dementia
      Two Alzheimer’s drugs offer hope to patients after decades of waiting

      In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

      Computer scan of a brain
    • Thursday, 4 May, 2023
      AstraZeneca PLC
      AstraZeneca chair says it is paying CEO enough to ward off US rivals

      Drugmaker’s chief executive Pascal Soriot had talks last year about a role with US group Biogen

      Michel Demaré of AstraZeneca
    • Thursday, 29 December, 2022
      Congress faults US regulator’s approval of Biogen Alzheimer’s drug

      Committees cite inappropriate collaboration between FDA and drugmaker

      A box of the Aduhelm drug
    • Friday, 2 December, 2022
      The editorial board
      A glimmer of hope in treating Alzheimer’s disease

      Dementia drug development, diagnostics and delivery still require much more investment

      A series of brightly coloured scans of brain activity
    • Tuesday, 29 November, 2022
      Eisai Co Ltd
      Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

      Shares fall 11% following two patient deaths in trials of lecanemab

      Haruo Naito, the 74-year-old chief executive of Japan’s Eisai
    • Monday, 28 November, 2022
      LexDrugs research
      Dementia/Biogen: causal controversy means investors must take a stance Premium content

      The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

    • Wednesday, 28 September, 2022
      Pharmaceuticals sector
      Biogen and Eisai shares surge after Alzheimer’s drug trial success

      Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

      A scan of a brain affected by Alzheimer’s disease
    • Friday, 23 September, 2022
      Health sector
      Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

      Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

      A section of a human brain with Alzheimer’s disease on display at the Museum of Neuroanatomy at the University at Buffalo, New York
    • Wednesday, 21 September, 2022
      Pharmaceuticals sector
      Biogen drug slows progress of motor neurone disease in landmark trial

      Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis

      Professor Pamela Shaw
    • Wednesday, 4 May, 2022
      FT News Briefing podcast8 min listen
      Draghi urges EU to abandon unanimity requirement

      Biogen chief to step down after the company’s Alzheimer’s drug flops

    • Tuesday, 3 May, 2022
      Biogen chief to step down after Alzheimer’s drug flops

      US biotech to dismantle sales infrastructure for treatment as it begins search for successor

      A Biogen facility in Cambridge, Massachusetts, US
    • Sunday, 17 April, 2022
      Anjana Ahuja
      Hasty approval for Alzheimer’s drug offers a cautionary tale

      FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

      A packet and vial of Aduhelm
    • Monday, 20 December, 2021
      Biogen halves price of Alzheimer’s drug after sales fall short

      Insurers’ reluctance to pay for Aduhelm treatment forces biotech to lower costs as EMA highlights safety concerns

      Woman walks passed Biogen sign
    • Wednesday, 17 November, 2021
      European regulators cast doubt on Biogen Alzheimer’s drug

      Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment

      Biogen headquarters
    • Wednesday, 20 October, 2021
      Biogen sells just $300,000 worth of contentious Alzheimer’s drug

      Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

      Aduhelm, Biogen’s controversial drug for early Alzheimer’s disease
    • Thursday, 22 July, 2021
      Biogen defends contentious $56,000 Alzheimer’s drug

      Pharma group blames ‘misinformation’ for overshadowing approval of therapy

      A sign at the Biogen facility in Massachusetts
    • Friday, 9 July, 2021
      US Food & Drug Administration
      FDA calls for probe of staff involved in divisive Alzheimer’s approval

      US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment

      Biogen’s Alzheimer’s drug Aduhelm
    • Monday, 5 July, 2021
      News in-depthPharmaceuticals sector
      Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

      Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

    • Wednesday, 16 June, 2021
      Pharmaceuticals sector
      Biogen’s Japanese partner calls for global action on Alzheimer’s

      Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

      A researcher works on the development of the medication aducanumab in Cambridge
    • Friday, 11 June, 2021
      The Big Read
      The Alzheimer’s economy: is the new $56,000-a-year drug worth it?

      US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high

    • Tuesday, 8 June, 2021
      The FT ViewThe editorial board
      How to make the most of the Alzheimer’s drug approval

      FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line

      The World Health Organization says there are nearly 10m new dementia cases every year, two-thirds of which are Alzheimer’s disease
    • Tuesday, 8 June, 2021
      Lex
      Biogen/Alzheimer’s: the high cost of hope Premium content

      Lofty prices reward risky, expensive research. But aducanumab’s pricing will raise eyebrows

    • Tuesday, 8 June, 2021
      Drug prices
      Biogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costs

      Campaigners hit out at high price for controversial treatment that has divided scientists

    • Monday, 7 June, 2021
      Pharmaceuticals sector
      Alzheimer’s drug from Biogen wins US approval

      FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy

      A vial and packaging for the drug Aduhelm, the brand name for aducanumab
    Previous page You are on page 1 Next page

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT Live
    US Pharma and Biotech Summit
    Exploring trends and innovations in life sciences across the United States
    Tuesday, 14 May 2024New York, NY, USA
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In